Publications by authors named "William Irvin"

Claim this Profile
O
Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.
Eleftherios P Mamounas, Hanna Bandos, Julia R White, Thomas B Julian, Atif J Khan, William J Irvin

N Engl J Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen.
Stephanie L Safgren, Vera J Suman, Roberto A Leon Ferre, Matthew L Kosel, Vered Stearns, William Irvin

Breast Cancer Res Treat· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial.
Hanna Bandos, Sungjin Kim, N Lynn Henry, Ron D Hays, Vinicius F Calsavara, William J Irvin

JNCI Cancer Spectr· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal patient-reported outcomes on genotype-guided irinotecan dosing: feasibility and clinical relevance.
Jonathan D Sorah, Allison M Deal, Sophia I Stein, Mattias Jonsson, Federico Innocenti, William Irvin

Oncologist· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer.
Hanna K Sanoff, Allison M Deal, Jai Patel, Jonathan D Sorah, Jacquelyne Gaddy, William Irvin

Oncologist· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A video intervention to improve patient understanding of tumor genomic testing in patients with cancer.
Deloris J Veney, Lai Y Wei, Amanda E Toland, Carolyn J Presley, Heather L Hampel, William J Irvin

Cancer Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal hyperglycemia thresholds in patients undergoing chemotherapy: a cross sectional study of oncologists' practices.
Teresa M Salgado, Poorva B Birari, Mona Alshahawey, Erin Hickey Zacholski, Emily Mackler, William J Irvin

Support Care Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial.
Wendy Y Chen, Karla V Ballman, Ann H Partridge, Olwen M Hahn, Frederick M Briccetti, William J Irvin

JAMA· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients with Cancer.
Deloris Veney, Lai Wei, Amanda E Toland, Carolyn J Presley, Heather Hampel, William J Irvin

medRxiv· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncologists' responsibility, comfort, and knowledge managing hyperglycemia in patients with cancer undergoing chemotherapy: a cross sectional study.
Teresa M Salgado, Rotana M Radwan, Erin Hickey Zacholski, Emily Mackler, Tonya M Buffington, William J Irvin

Support Care Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.
Benjamin J Bulen, Nickolay A Khazanov, Daniel H Hovelson, Laura E Lamb, Marc Matrana, William Irvin

Cancer Res Commun· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.
Scott A Tomlins, Nickolay A Khazanov, Benjamin J Bulen, Daniel H Hovelson, Melissa J Shreve, William Irvin

Commun Med (Lond)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
Beverly Moy, R Bryan Rumble, Steven E Come, Nancy E Davidson, Angelo Di Leo, William J Irvin

J Clin Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
Ciara C O'Sullivan, Karla V Ballman, Linda McCall, Anuhya Kommalapati, Tyler Zemla, William J Irvin

Future Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
Natasha B Leighl, Mary W Redman, Naiyer Rizvi, Fred R Hirsch, Philip C Mack, William J Irvin

J Immunother Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples.
Scott A Tomlins, Daniel H Hovelson, Jennifer M Suga, Daniel M Anderson, Han A Koh, William J Irvin

JCO Precis Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers.
Leonid B Reshko, Sujith Baliga, Edwin F Crandley, I V Harry Lomas, Martin K Richardson, William Irvin

Gynecol Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereotactic body radiation therapy in the treatment of ovarian cancer.
Roman O Kowalchuk, Michael R Waters, K Martin Richardson, Kelly Spencer, James M Larner, William P Irvin

Radiat Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
Jared M Weiss, Nathan Pennell, Allison M Deal, Daniel Morgensztern, Daniel S Bradford, William Irvin

Cancer· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.
Lauren A Marcath, Allison M Deal, Emily Van Wieren, William Danko, Christine M Walko, William J Irvin

Pharmacogenet Genomics· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
Daniel L Hertz, Allison Deal, Joseph G Ibrahim, Christine M Walko, Karen E Weck, William J Irvin

Oncologist· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.
Daniel L Hertz, Anna C Snavely, Howard L McLeod, Christine M Walko, Joseph G Ibrahim, William J Irvin

Br J Clin Pharmacol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.
Costanza Paoletti, Yufeng Li, Maria C Muñiz, Kelley M Kidwell, Kimberly Aung, William J Irvin

Clin Cancer Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.
Andres Forero-Torres, Katherine E Varley, Vandana G Abramson, Yufeng Li, Christos Vaklavas, William J Irvin

Clin Cancer Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the utility of whole genome amplified DNA as a template for DMET Plus array.
Yi Jing He, Anne D Misher, William Irvin, Alison Motsinger-Reif, Howard L McLeod

Clin Chem Lab Med· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis